Eclipsebio Introduces eCOMPASS™: Revolutionizing RNA Therapy Development with AI

Eclipsebio Launches eCOMPASS™ for RNA Therapeutics

Eclipse Bioinnovations, Inc., a prominent player in RNA therapeutics, has recently unveiled its eCOMPASS™ platform. This innovative lab-in-the-loop solution is designed to streamline and integrate RNA therapeutic development processes, which are crucial for advancing vaccines, CAR-T therapies, gene editing, and protein replacement strategies.

The eCOMPASS™ platform combines machine learning with state-of-the-art RNA design, providing a comprehensive solution that covers the entire continuum from design to characterization. The launch builds on Eclipsebio's acquisition of Terrain Bio, allowing the company to merge AI-driven RNA sequence design capabilities with robust research and development manufacturing features.

Core Components of eCOMPASS™

The platform revolves around three core functionalities: design, make, and test, functioning in a continuous feedback loop. This interplay enables rapid iteration based on empirical data, vital for refining RNA designs.

1. Design: At the heart of the eCOMPASS™ platform lies eNAVIGATE™, Eclipsebio's AI optimization tool. By leveraging machine learning trained on extensive proprietary datasets, eNAVIGATE™ confidently produces RNA candidates that are meticulously optimized for various parameters including expression levels, stability, and manufacturability.

2. Make: Following the design stage, RNA sequences progress to rapid prototyping at research and development scale. This phase accommodates the generation of linear mRNAs exceeding 10 kb, ensuring quality control in terms of yield and integrity.

3. Test: RNA candidates undergo rigorous testing and analysis through the eMERGE™ platform. This stage employs deep sequencing techniques, delivering nucleotide-level measurements of critical factors such as structure, translation dynamics, integrity, and purity. Such precision surpasses conventional quality control methods, ultimately allowing for a deeper understanding of RNA functionality.

Significant Outcomes

Early results from case studies using eCOMPASS™ have been remarkably positive. In one internal evaluation focused on developing a gene editing therapy, the platform demonstrated how eCOMPASS-designed Cas9 mRNA candidates achieved a staggering 400% increase in protein expression and a 58% elevation in editing efficiency when compared to baseline methodologies. These improvements were achieved through the innovative combination of empirical feedback and optimization, establishing eCOMPASS™ as a powerful tool for RNA therapeutic advancement.

Eclipsebio's Co-Founder and CEO, Dr. Peter Chu, highlighted the company's extensive background: "By leveraging data generated over nine years, we propel our partners' programs forward, effectively providing a single platform where AI-driven design and detailed characterization reinforce each other since the beginning of the process."

Dr. Eckhard Jankowsky, a member of the Scientific Advisory Board and former Vice President of RNA Science at Moderna, emphasized the gap that eCOMPASS™ fills within the field of RNA therapeutics. He stated, "The RNA therapeutics space has struggled for a comprehensive platform that effectively connects sequence design with deep mechanistic characterization. Many programs rely primarily on computational methods, consequently overlooking critical nucleotide-level insights necessary for optimizing RNA designs. eCOMPASS™ changes this narrative."

Potential Impact on the Industry

With eCOMPASS™, research institutions and biotech companies can expect not only to streamline their RNA therapeutic development processes but also to significantly enhance their efficiency and effectiveness in producing therapies that are ready for clinical trials. This platform serves as a clear example of how AI and advanced sequencing methodologies can be harnessed to transform biopharmaceutical research practices.

To discover how eCOMPASS™ can elevate your RNA therapeutic program, reach out directly to Eclipsebio.

About Eclipsebio

Eclipsebio is a distinguished biotechnology firm located in San Diego, specializing in the amalgamation of AI-powered sequence design, rapid prototyping, and sequencing-based analytics for RNA drug development. With a wealth of experience in supporting early research stages through to preclinical therapeutic development, Eclipsebio is committed to delivering deep insights into RNA and therapeutic biology. The company partners with biopharma entities and offers project-based services to academic institutions.

For more information about their innovative solutions, visit Eclipsebio's website.